| Cat.No. | Name | Information |
|---|---|---|
| M5149 | GSK-J4 | GSK-J4 is a cell permeable procompound rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor. |
| M5762 | Mebhydrolin napadisylate | Mebhydrolin (napadisylate) is an antihistamine, used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis. |
| M5213 | ORY-1001 (Iadademstat) | ORY-1001 (RG-6016) is the only dual KDM1A/LSD1 inhibitor, and it is also the only KDM1A inhibitor in development for the treatment of neurodegenerative disease. |
| M5212 | GSK2879552 | GSK2879552 is an effective, selective, bioactive and irreversible LSD1 inhibitor with Kiapp=1.7 μM. |
| M5136 | GSK-LSD1 dihydrochloride | GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B). |
| M2897 | OG-L002 | OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively. |
| M2731 | GSK-J4 hydrochloride | GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 hydrochloride is a cell permeable procompound of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. |
| M2730 | GSK-J1 | GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 of 60 nM towards KDM6B. GSK J1 is selective for the H3K27 demethylases JMJD3 and UTX. |
| M2275 | JIB-04 | JIB-04 is a selective inhibitor of Jumonji histone demethylase with IC50 values of 230, 340, 435, 445, 855 and 1100 nM for JARID1A, JMJD2E, JMJD2B, JMJD2A, JMJD3 and JMJD2C respectively. |
| M56055 | PFI-90 | PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. |
| M56054 | CPI-4203 | CPI-4203 is a potent KDM5A inhibitor with an IC50 of 250 nM. |
| M56053 | KDM2B-IN-4 | KDM2B-IN-4 is a histone demethylase KDM2B inhibitor. |
| M56052 | Zavondemstat | Zavondemstat (QC8222; TACH 101) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity. |
| M56051 | Zavondemstat L-lysine | Zavondemstat (QC8222; TACH 101) (L-lysine) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity. |
| M45256 | INCB059872 | INCB059872 is a potent, orally active, selective and irreversible inhibitor of lysine-specific demethylase 1 (LSD1) in myeloid leukemia. |
| M45100 | KDM2A/7A-IN-1 | KDM2A/7A-IN-1 is a first-in-class, selective, cell-permeable inhibitor of the histone lysine demethylase KDM2A/7A, with an IC50 value of 0.16 μM for KDM2A, 75-fold more selective than other JmjC lysine demethylases, and with no effect on methyltransferases or histone acetyltransferases. KDM2A was 75 times more selective than other JmjC lysine demethylases and had no effect on methyltransferases and histone acetyltransferases. |
| M41684 | NCD38 TFA | NCD38 TFA is a LSD1-selective inhibitor. |
| M41683 | LSD1-IN-26 | LSD1-IN-26 is a potent LSD1 inhibitor, with an IC50 of 25.3 nM. |
| M41682 | JMJD6-IN-1 | JMJD6-IN-1 is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. |
| M41681 | LSD1-IN-25 | LSD1-IN-25 is a potent, selective and orally active LSD1 inhibitor with an IC50 of 46 nM (Ki = 30.3 nM). |
| M41680 | FY-21 | FY-21 is a selective inhibitor of LSD1 (IC50=340 nM), with anti-proliferation and anti-colony formation activities. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
